A Cohort Study of Patients With Metastatic Colorectal Cancer Treated With Avastin® as First-line Therapy for Liver Metastases Considered as Potentially Resectable

Primary Objective: evaluate the efficacy and safety of bevacizumab as first-line treatment in participants with colorectal cancer and potentially resectable liver metastases. Secondary Objectives: - To describe patients’ characteristics treated with Avastin®, - To describe the subgroup of patients with unresected missing metastases, with or without surgery, - To describe criteria used to define unresectability, - To describe progression-free survival in all patients, - To describe relapse-free survival in all resected patients with no DMD, - To describe overall survival in all patients, - To describe histopathological response in resected patients, - To describe Avastin® treatment modalities, - To describe safety profile of Avastin®.